B. Riley equity line of credit
Company: Core Scientific
The claim, verbatim
The Company has the right to sell to B. Riley Principal Capital II up to $100,000,000 of common stock shares under an equity purchase agreement entered into on July 20, 2022.
Source (primary)
Core Scientific 8-K filed 2022-10-27 (SEC EDGAR, sec_filing)
View cached copy (2026-09-13)Live source ↗
Quote: “On July 20, 2022, the Company entered into an equity purchase agreement with B. Riley Principal Capital II ("B. Riley"), pursuant to which, the Company has the right to sell to B. Riley up to $100,000,000 of shares of the Company's common stock”
How we checked this
This claim has not yet been checked assertion-by-assertion against its source. It carries a cited source and quote, but the deeper check has not run. When it does, the result appears here whatever it says.
Additional evidence
confirms Core Scientific 8-K filed 2022-10-27
Quote: “On July 20, 2022, the Company entered into an equity purchase agreement with B. Riley Principal Capital II ("B. Riley"), pursuant to which, the Company has the right to sell to B. Riley up to $100,000,000 of shares of the Company's common stock”